INFECTORY: The Netherlands Builds GMP Manufacturing Capacity for Clinical Phage Research
The Netherlands is developing a dedicated infrastructure for manufacturing pharmaceutical-grade bacteriophages, addressing one of the less visible but increasingly important barriers to clinical phage therapy: producing viruses consistently, safely and according to Good Manufacturing Practice standards.
The four-year INFECTORY project is led by INFECTA together with Leiden University Medical Center, UMC Utrecht, FAST and real-estate partner AHAM, with InFECT-NL also involved in the broader collaboration. Supported through PharmaNL and funding made possible by ZonMw, the initiative aims to establish shared Dutch capacity for small-scale GMP production of bacteriophages for clinical research, personalized treatments and other controlled medical applications.
PharmaNL highlighted the programme on July 9, 2026 as a new Shared Development Infrastructure project. The initiative had previously been selected under the PharmaNL SDI 2025 funding round, alongside infrastructure projects targeting other emerging pharmaceutical technologies. A public funding amount specifically allocated to INFECTORY has not been disclosed in the project announcements reviewed by The Phage Therapy.
The project addresses a central problem confronting the clinical development of bacteriophages. Researchers can isolate promising viruses against multidrug-resistant bacteria, characterize their genomes and demonstrate antibacterial activity in laboratory experiments, yet translating those phages into medicines requires an entirely different layer of infrastructure.
A bacteriophage preparation intended for administration to patients cannot simply consist of a laboratory lysate containing active viruses. Manufacturing needs to control the bacterial host used to amplify the phage, remove bacterial debris and potentially harmful contaminants, establish the identity and concentration of the viral product, verify microbiological purity and maintain reproducibility across batches.
For Gram-negative production hosts, endotoxin removal is particularly important because bacterial lipopolysaccharide can trigger severe inflammatory responses if present at excessive concentrations in a pharmaceutical preparation. Other manufacturing concerns include sterility, residual host-cell DNA and proteins, genetic characterization of the phage, stability during storage and traceability of every material and process involved in production.
These requirements become considerably more demanding once phages enter formal clinical research. Good Manufacturing Practice is designed to ensure that medicinal products are consistently produced and controlled according to predefined quality standards. For phages, applying this framework is challenging because the active ingredient is not a conventional chemical molecule but a self-replicating biological entity produced inside living bacteria.
INFECTORY is intended to create an environment where those challenges can be handled systematically. According to PharmaNL, the consortium will design and establish a controlled manufacturing environment equipped for work with microorganisms and, where required, genetically modified bacterial hosts. Specialized production equipment, analytical methods, process validation, quality-control procedures and regulatory documentation will all form part of the infrastructure.
Traceability is a particularly important element. Every stage of production must be documented so that researchers can establish where biological materials originated, how the phage was propagated and purified, which analytical tests were performed and whether the final batch met its predefined specifications.
The facility is not intended primarily for large commercial production. Instead, INFECTORY is being developed around relatively small GMP batches appropriate for early-phase clinical studies and personalized treatment. That model reflects an unusual characteristic of phage therapy: in some applications, the relevant bacteriophage may need to be selected according to the bacterial isolate recovered from an individual patient.
Such personalization creates an economic and manufacturing problem. Conventional pharmaceutical manufacturing is optimized around producing very large quantities of an identical product, allowing fixed development and quality-control costs to be spread across many doses. Personalized phage therapy can require relatively small quantities of several different viruses, each of which still needs appropriate characterization and quality control.
INFECTORY is attempting to design infrastructure around precisely this constraint. The consortium describes a make-to-order model in which phages can be produced when required rather than manufacturing large quantities of every candidate in advance. Centralized storage and simplified, standardized manufacturing pathways are also planned to maintain quality while reducing costs and avoiding unnecessary production.
This approach could be particularly useful for phage banks. Hospitals and research groups can maintain collections containing viruses active against clinically important pathogens, but converting every phage in such a collection into a fully manufactured medicinal product would be prohibitively expensive. A shared production facility could instead prioritize specific candidates once a clinical or research need has been identified.
The project expects eventually to manufacture several high-quality phage products each year. FAST has described an initial production capacity of approximately three to four products annually, with the possibility of further expansion. That scale reinforces the project's role as a specialized translational infrastructure rather than an industrial mass-production plant.
A major objective is to make this capacity available beyond the founding partners. Academic laboratories, hospitals, start-ups and scale-ups developing phage-based approaches are expected to be able to access the infrastructure rather than having to construct separate GMP manufacturing capabilities themselves.
This shared model addresses one of the structural weaknesses of the current phage-therapy ecosystem. An academic laboratory may possess extensive microbiological expertise and a valuable collection of phages without having the cleanrooms, validated analytical methods, regulatory staff or pharmaceutical quality system required for clinical manufacturing. Building those capabilities specifically for one research project can be financially unrealistic.
INFECTORY therefore separates phage discovery from the need for every discovery group to become a pharmaceutical manufacturer. A research team could identify a promising candidate and potentially transfer it into a shared infrastructure designed specifically to transform experimental phage material into a product suitable for controlled clinical investigation.
For small companies, the same model could reduce one of the largest early capital requirements in therapeutic development. Building and qualifying a dedicated manufacturing environment before a clinical programme has generated evidence of efficacy represents a substantial financial risk. Access to shared infrastructure could allow developers to produce early clinical batches without immediately financing their own facility.
This problem is particularly acute in phage therapy because the commercial model remains uncertain. Many phages can be isolated from the environment, therapies may require mixtures or personalized selections, and the regulatory path continues to evolve. These characteristics can make investors reluctant to finance expensive manufacturing infrastructure before the clinical and commercial models have been validated.
FAST has explicitly identified this market gap as one of the reasons public investment is important. The scientific need for high-quality clinical phage research already exists, while the economic incentives for private actors to build broad-access infrastructure remain comparatively weak.
The Dutch project therefore combines public funding with academic, clinical and private expertise. INFECTA contributes infectious-disease clinical research and project leadership, while LUMC and UMC Utrecht provide medical, microbiological and pharmaceutical expertise. FAST contributes experience in sustainable therapy development and translation, while AHAM is involved on the real-estate and infrastructure side.
The participation of LUMC is particularly relevant to the pharmaceutical-quality component. Qualified Persons are central to European GMP manufacturing because they are responsible for certifying that batches intended for clinical use have been produced and tested in accordance with relevant requirements. PharmaNL specifically highlights Pauline Meij of LUMC as the Qualified Person involved in the programme.
The project has been structured around several development stages rather than treating construction of the facility as the only objective. ZonMw describes an initial transition of phage-production processes toward GMP standards, followed by construction of the INFECTORY facility and then a pilot project intended to demonstrate that the infrastructure can actually manufacture appropriate products.
That sequencing matters because a GMP facility is not created merely by installing specialized equipment. Manufacturing processes themselves need to be defined and validated, analytical assays need acceptable performance characteristics, personnel require training, materials and suppliers must be controlled, environmental monitoring must be established and deviations need documented procedures for investigation.
For bacteriophages, process development can be particularly complex because different viruses do not necessarily behave identically during amplification and purification. Phages can differ greatly in capsid structure, genome size, stability, aggregation behaviour and sensitivity to changes in temperature, pH or chemical conditions.
The bacterial production strain introduces additional variability. Phage amplification depends on the biological state of the host, culture conditions, multiplicity of infection and timing of harvest. A production process optimized for one phage–bacterium pair may therefore not transfer directly to another.
INFECTORY's proposed standardized manufacturing pathways will have to accommodate this biological diversity while retaining sufficient control for pharmaceutical-quality production. Achieving that balance is one of the larger technical challenges facing decentralized or personalized phage manufacturing.
Clinical research is another central objective. Meta Roestenberg, CEO of INFECTA and a professor at Leiden University Medical Center, has emphasized the need for controlled studies capable of determining which patients benefit from bacteriophages and under which circumstances.
This represents an important transition for a field that has historically relied heavily on individual compassionate-use cases. Such treatments can be medically important and have generated valuable observations, but heterogeneous phage products, different routes of administration, simultaneous antibiotic therapy and widely different infections often make it difficult to determine which factors produced a clinical outcome.
Controlled clinical trials can address those questions more rigorously, but they require standardized medicinal products. If different patients receive preparations produced by unrelated laboratories under different protocols, variation in manufacturing itself can become a confounding variable.
Reliable GMP access therefore affects more than regulatory compliance. It also affects scientific interpretation. Standardized production makes it easier to determine whether differences between patients reflect biological response to the therapy rather than inconsistencies between phage preparations.
INFECTORY could consequently help create the evidence needed to determine appropriate dosing, administration routes, treatment schedules and patient-selection criteria. These questions remain incompletely resolved across much of phage therapy and cannot be answered through manufacturing infrastructure alone, but producing consistent investigational products is a prerequisite for answering them properly.
The Dutch project also proposes a pathway for individualized patient access. ZonMw describes a national expert group intended to provide a transparent gateway for considering use in individual patients, while regulators, hospitals and insurers are expected to be involved in implementation.
That model reflects the unusual position phage therapy occupies between experimental medicine and conventional pharmaceutical development. For patients with severe infections caused by bacteria resistant to available antibiotics, clinicians may seek access to bacteriophages before large randomized trials have established standardized products for every pathogen and indication.
Centralizing expertise may help ensure that such requests are evaluated consistently and that data generated during treatment contribute to broader clinical knowledge rather than remaining isolated experiences. The project also aims for non-discriminatory access to the infrastructure and a transparent cost-based model.
INFECTA describes the collaboration as not-for-profit and proposes first-come, first-served access for manufacturing capacity. It also intends to share manufacturing knowledge and data through open-science principles. If implemented as planned, this would distinguish INFECTORY from infrastructure built exclusively around a proprietary commercial pipeline.
Another objective is reducing dependence on imported phage preparations. European clinicians and researchers have sometimes needed to obtain therapeutic phages or manufacturing support from institutions outside their own country, which can introduce delays, logistical complexity and differences in manufacturing standards.
A national GMP infrastructure would not eliminate international collaboration, nor would it mean that every useful therapeutic phage needs to originate in the Netherlands. It could instead allow promising phages from multiple sources to be transferred into a standardized Dutch manufacturing pathway before use in local clinical research.
Centralized storage could strengthen this model by retaining characterized materials and manufacturing intermediates under controlled conditions. Over time, such an infrastructure could accumulate experience across multiple phage products, allowing analytical methods and production processes to become progressively more efficient.
The project is therefore as much about learning how to manufacture phages repeatedly as it is about constructing a physical facility. Every manufactured batch can generate information on propagation yield, purification recovery, stability, quality-control parameters and production costs.
Those data could become valuable for determining which phages are realistic pharmaceutical candidates. Two viruses with similar antibacterial activity may differ substantially in manufacturability. One may replicate to very high titres, tolerate purification and remain stable for long periods, while another may be difficult to amplify or rapidly lose infectivity during storage.
Manufacturability could consequently become another selection criterion alongside host range, killing kinetics, genetic safety and ability to overcome bacterial defence systems. As phage therapy becomes more technologically mature, choosing viruses that can be reliably produced may become increasingly important.
The project also arrives during broader European efforts to clarify the regulatory treatment of bacteriophages. Phages present unusual challenges because therapeutic compositions may need to change when bacterial resistance emerges or when treatment must be adapted to an individual pathogen. Conventional pharmaceutical frameworks were largely developed around stable active ingredients and fixed formulations.
A flexible manufacturing infrastructure could provide practical experience relevant to these regulatory discussions. Demonstrating that different phages can move through standardized production and analytical workflows may help establish which aspects of manufacturing can remain platform-based and which need to be validated separately for each virus.
This is especially important for phage cocktails. Combining several bacteriophages can broaden bacterial coverage or reduce the probability that resistance to a single virus causes treatment failure, but every added component increases manufacturing and quality-control complexity.
Each phage may require separate amplification, purification and characterization before combination into the final medicinal product. Manufacturers must also determine whether the components remain stable together and whether one phage affects recovery or quantification of another.
A facility specifically designed around phages can build analytical strategies for these problems rather than adapting conventional biologics infrastructure on a case-by-case basis.
The INFECTORY programme should nevertheless not be interpreted as confirmation that the Netherlands already possesses a newly authorized, fully operational GMP phage factory. The July PharmaNL announcement describes infrastructure that is being designed and built over a four-year project.
Regulatory approvals, validation, construction and qualification remain part of that development process. PharmaNL states that the consortium aims to begin producing multiple batches annually during the final phase of the programme, rather than presenting such production as a capability already operating at full scale today.
Similarly, the project does not itself establish that phage therapy is clinically effective for any particular infection. Its purpose is to provide the manufacturing conditions needed to conduct the controlled research capable of producing stronger evidence.
This distinction makes INFECTORY different from a therapeutic programme developing one specific phage cocktail against one pathogen. Its potential value lies in supporting many programmes by solving an infrastructure bottleneck common to the field.
A successful shared facility could provide Dutch academic groups and small biotechnology companies with a route from experimental phage discovery to pharmaceutical-quality material without requiring every organisation to reproduce the same expensive manufacturing system.
It could also provide a useful model for other European countries considering how to support personalized or small-batch phage therapy. Centralized expertise combined with flexible, on-demand production may prove more economically realistic than building numerous separate low-volume facilities.
Much will depend on execution. Developing validated processes that are flexible enough for biologically diverse phages, maintaining affordable access and integrating personalized production with European medicinal-product requirements are substantial challenges.
The programme's success will therefore be measured not simply by whether a building becomes operational, but by whether it can reliably transform experimental phages into traceable, reproducible and clinically usable products at a cost compatible with academic and early-stage development.
For phage therapy, manufacturing is sometimes treated as a downstream problem to be addressed after efficacy has been demonstrated. INFECTORY takes almost the opposite approach: without accessible pharmaceutical-quality production, obtaining convincing clinical evidence becomes considerably harder in the first place.
By bringing together clinical researchers, hospitals, manufacturing expertise, regulators and infrastructure partners, the Netherlands is attempting to build the missing bridge between phages discovered in laboratories and phages that can be systematically evaluated as medicines.
If the four-year project reaches its objectives, INFECTORY will not answer whether phage therapy works for every resistant infection. It could, however, provide something the field needs before that question can be answered reliably: a reproducible way to manufacture the bacteriophages required for controlled clinical research.
Sources :
PharmaNL — “A New Generation of Infection Control: PharmaNL Project INFECTORY Builds Dutch GMP Infrastructure for Bacteriophages,” July 9, 2026. The official feature describes the four-year consortium, the planned GMP manufacturing environment, validation and regulatory requirements, centralized storage and the objective of producing multiple phage batches annually for clinical studies. PharmaNL
https://www.pharmanl.org/en/news/a-new-generation-of-infection-control-infectory/
ZonMw — INFECTORY project. The project description outlines the three-stage development strategy, centralized storage, make-to-order production, national expert access pathway and involvement of regulators, hospitals and insurers. projecten.zonmw.nl
https://projecten.zonmw.nl/nl/project/infectory
INFECTA — “INFECTORY receives funding to advance phage therapy in The Netherlands,” March 25, 2026. INFECTA describes the planned shared GMP facility, access for academic groups and companies, personalized and early-phase clinical production, transparent cost-based access and the project's not-for-profit model. INFECTA
https://infecta.org/news/infectory-receives-funding-to-advance-phage-therapy-in-the-netherlands/
FAST — “An important step forward in the fight against antimicrobial resistance,” March 25, 2026. FAST reports plans for small-scale GMP production and an initial expected capacity of approximately three to four high-quality phage products per year. fast.nl
https://www.fast.nl/en/news/an-important-step-forward-in-the-fight-against-antimicrobial-resistance-amr/
PharmaNL — “Four New Projects Launch under Shared Development Infrastructure,” February 26, 2026. INFECTORY was one of four projects selected in the Shared Development Infrastructure 2025 call, which is funded through the Dutch National Growth Fund and administered with ZonMw. PharmaNL
https://www.pharmanl.org/en/news/four-new-projects-launch-under-sdi/
LUMC — Academic Pharma: Manufacturing. LUMC describes the transition from research-scale active ingredients toward GMP manufacturing required for clinical studies and pharmaceutical development. lumc.nl
https://www.lumc.nl/en/research/themes-for-innovation/academic-pharma/manufacturing/
.png){kind=logo}
Comments
Post a Comment